UniSuper Management Pty Ltd Boosts Stake in Becton, Dickinson and Company $BDX

UniSuper Management Pty Ltd boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 31.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,352 shares of the medical instruments supplier’s stock after acquiring an additional 7,241 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Becton, Dickinson and Company were worth $5,681,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC lifted its position in shares of Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after acquiring an additional 1,354 shares during the period. Park Avenue Securities LLC purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $757,000. Congress Asset Management Co. grew its holdings in shares of Becton, Dickinson and Company by 6.0% in the 2nd quarter. Congress Asset Management Co. now owns 2,005 shares of the medical instruments supplier’s stock worth $345,000 after acquiring an additional 113 shares during the period. Finally, CX Institutional increased its stake in Becton, Dickinson and Company by 13.4% in the 2nd quarter. CX Institutional now owns 1,671 shares of the medical instruments supplier’s stock valued at $288,000 after purchasing an additional 198 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 2,605 shares of company stock valued at $524,643. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $201.84 on Monday. The stock has a market capitalization of $57.51 billion, a P/E ratio of 34.62, a P/E/G ratio of 2.23 and a beta of 0.23. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The firm’s 50-day moving average is $197.40 and its two-hundred day moving average is $190.53.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were paid a dividend of $1.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Bank of America boosted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Jefferies Financial Group lifted their target price on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada increased their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Four analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.